MDS

Middle East Cybersecurity Market worth $23.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 5, 2024

The exponential growth of the services segment in the Middle East Cybersecurity Market is driven by the multifaceted challenges posed by evolving cyber threats.

Key Points: 
  • The exponential growth of the services segment in the Middle East Cybersecurity Market is driven by the multifaceted challenges posed by evolving cyber threats.
  • Moreover, the rising demand for cyber-insurance contributes significantly to the burgeoning services sector, establishing it as the fastest-growing segment in the Middle East Cybersecurity Market.
  • The on-premises segment has the largest market size in the Middle East Cybersecurity Market for various reasons, such as the paramount importance placed on data privacy concerns.
  • Investors, service providers, and cybersecurity vendors wishing to take advantage of the region's potential for cybersecurity market growth and meet changing cybersecurity needs will find great investment opportunities in the Middle East due to the growing need for cybersecurity solutions.

Middle East Cybersecurity Market worth $23.4 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 5, 2024

The exponential growth of the services segment in the Middle East Cybersecurity Market is driven by the multifaceted challenges posed by evolving cyber threats.

Key Points: 
  • The exponential growth of the services segment in the Middle East Cybersecurity Market is driven by the multifaceted challenges posed by evolving cyber threats.
  • Moreover, the rising demand for cyber-insurance contributes significantly to the burgeoning services sector, establishing it as the fastest-growing segment in the Middle East Cybersecurity Market.
  • The on-premises segment has the largest market size in the Middle East Cybersecurity Market for various reasons, such as the paramount importance placed on data privacy concerns.
  • Investors, service providers, and cybersecurity vendors wishing to take advantage of the region's potential for cybersecurity market growth and meet changing cybersecurity needs will find great investment opportunities in the Middle East due to the growing need for cybersecurity solutions.

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

Retrieved on: 
Thursday, January 25, 2024

The new analysis of data from the Phase 1 part of the trial explores the 100% overall response rate (ORR) achieved among both the higher-risk frontline and HMA-failed MDS patients treated with a bexmarilimab/azacitidine combination – 5 out of 5 patients in each population – and examines previous therapies in the patients’ treatment pathways.

Key Points: 
  • The new analysis of data from the Phase 1 part of the trial explores the 100% overall response rate (ORR) achieved among both the higher-risk frontline and HMA-failed MDS patients treated with a bexmarilimab/azacitidine combination – 5 out of 5 patients in each population – and examines previous therapies in the patients’ treatment pathways.
  • “Patients with high-risk MDS who have failed HMA therapy face a poor prognosis and median overall survival in refractory MDS is just 4-6 months with no viable treatment options.
  • Yet here we have data showing that patients are surpassing anticipated survival rates and maintaining remission.
  • It is remarkable to see patients going into remission with bexmarilimab/azacitidine after showing disease progression on all the leading azacitidine combinations such as venetoclax, sabatolimab and magrolimab.

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Thursday, January 18, 2024

WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online. The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) (NCT05473910). The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.

Key Points: 
  • WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online.
  • The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
  • The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.
  • Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center)
    A copy of the presentation materials will be added to the “ Events and Presentations ” section of the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.

Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial

Retrieved on: 
Tuesday, January 9, 2024

TURKU, Finland and BOSTON, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announced that the first patient has been dosed in Phase 2 of the BEXMAB trial that evaluates the safety and efficacy of bexmarilimab, in combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS), an aggressive myeloid leukemia with very few treatment options.

Key Points: 
  • The ongoing, randomized parallel-assigned Phase 2 part is enrolling 32 HMA-failed MDS patients at 3 mg/kg and 6 mg/kg dose levels of bexmarilimab.
  • Patients are being randomized 1:1 between the doses before moving into a Phase 2/3 study expansion.
  • Post selection of final dosing, Faron intends to discuss a potential registrational study plan with the FDA.
  • The Company’s key focus is to pursue an accelerated path to approval in refractory higher risk MDS, where no treatment option exists.

Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals

Retrieved on: 
Monday, January 8, 2024

Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.
  • Today Schrödinger announced an expanded, three-year, software agreement with Eli Lilly and Company.
  • The three-year agreement builds on the collaboration established in 2022.
  • Schrödinger will provide advanced support to ensure full integration and optimization of the platform across Lilly’s research sites.

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Retrieved on: 
Monday, January 8, 2024

This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.

Key Points: 
  • This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.
  • Over the next four years, we anticipate the filing of at least six new INDs, reflecting the productivity of our precision medicine platform.
  • This is all supported by our cash and equivalents position of approximately $259.9 million as of September 30, 2023.”
    FHD-286.
  • Foghorn is engaged in a strategic collaboration with Loxo@Lilly and continues to advance the BRM selective inhibitor and degrader programs along with other undisclosed programs.

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced its recent accomplishments, including the authorization by the European Medicines Agency (EMA) of the Company’s Clinical Trial Applications (CTA) for its Phase 1b/2a trials of briquilimab in CIndU and CSU, and outlined its corporate priorities and anticipated milestones for 2024. Called SPOTLIGHT – “Study (Phase 1b/2a) Of subcuTaneous brIquilimab in patients diaGnosed with cHronic inducible urTicaria” – the CIndU study will evaluate single doses of subcutaneous briquilimab in adult patients with cold urticaria or symptomatic dermographism.

Key Points: 
  • “2023 was a strategically important year for Jasper,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • “We secured IND clearance and CTA authorization for the Phase 1b/2a BEACON study of briquilimab in CSU and successfully dosed the first patient.
  • Our achievements in 2023 set the stage for a transformational year ahead with multiple key clinical milestones on the horizon across multiple indications.
  • Strengthened the organization with key leadership appointments including Thomas Wiggans as Chairperson of the Board of Directors, Scott Brun, M.D.

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024

WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings, has issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.

Key Points: 
  • WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings, has issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.
  • Our strategy is to leverage these innovative and complementary platforms to develop powerful, personalized cell-based treatments to improve outcomes for patients with cancer.
  • As we look to 2024, we see enormous potential to advance our pipeline and achieve meaningful growth milestones.
  • On behalf of the entire Coeptis team, I wish you all a happy and healthy 2024.